LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14201

Search options

  1. Article ; Online: Measurement of the Ratios of Branching Fractions R(D^{*}) and R(D^{0}).

    Aaij, R / Abdelmotteleb, A S W / Abellan Beteta, C / Abudinén, F / Ackernley, T / Adeva, B / Adinolfi, M / Adlarson, P / Afsharnia, H / Agapopoulou, C / Aidala, C A / Ajaltouni, Z / Akar, S / Akiba, K / Albicocco, P / Albrecht, J / Alessio, F / Alexander, M / Alfonso Albero, A /
    Aliouche, Z / Alvarez Cartelle, P / Amalric, R / Amato, S / Amey, J L / Amhis, Y / An, L / Anderlini, L / Andersson, M / Andreianov, A / Andreotti, M / Andreou, D / Ao, D / Archilli, F / Artamonov, A / Artuso, M / Aslanides, E / Atzeni, M / Audurier, B / Bachiller Perea, I B / Bachmann, S / Bachmayer, M / Back, J J / Bailly-Reyre, A / Baladron Rodriguez, P / Balagura, V / Baldini, W / Baptista de Souza Leite, J / Barbetti, M / Barlow, R J / Barsuk, S / Barter, W / Bartolini, M / Baryshnikov, F / Basels, J M / Bassi, G / Batsukh, B / Battig, A / Bay, A / Beck, A / Becker, M / Bedeschi, F / Bediaga, I B / Beiter, A / Belin, S / Bellee, V / Belous, K / Belov, I / Belyaev, I / Benane, G / Bencivenni, G / Ben-Haim, E / Berezhnoy, A / Bernet, R / Bernet Andres, S / Berninghoff, D / Bernstein, H C / Bertella, C / Bertolin, A / Betancourt, C / Betti, F / Bezshyiko, Ia / Bhasin, S / Bhom, J / Bian, L / Bieker, M S / Biesuz, N V / Billoir, P / Biolchini, A / Birch, M / Bishop, F C R / Bitadze, A / Bizzeti, A / Blago, M P / Blake, T / Blanc, F / Blank, J E / Blusk, S / Bobulska, D / Boelhauve, J A / Boente Garcia, O / Boettcher, T / Boldyrev, A / Bolognani, C S / Bolzonella, R / Bondar, N / Borgato, F / Borghi, S / Borsato, M / Borsuk, J T / Bouchiba, S A / Bowcock, T J V / Boyer, A / Bozzi, C / Bradley, M J / Braun, S / Brea Rodriguez, A / Brodzicka, J / Brossa Gonzalo, A / Brown, J / Brundu, D / Buonaura, A / Buonincontri, L / Burke, A T / Burr, C / Bursche, A / Butkevich, A / Butter, J S / Buytaert, J / Byczynski, W / Cadeddu, S / Cai, H / Calabrese, R / Calefice, L / Cali, S / Calvi, M / Calvo Gomez, M / Campana, P / Campora Perez, D H / Campoverde Quezada, A F / Capelli, S / Capriotti, L / Carbone, A / Cardinale, R / Cardini, A / Carniti, P / Carus, L / Casais Vidal, A / Caspary, R / Casse, G / Cattaneo, M / Cavallero, G / Cavallini, V / Celani, S / Cerasoli, J / Cervenkov, D / Chadwick, A J / Chahrour, I / Chapman, M G / Charles, M / Charpentier, Ph / Chavez Barajas, C A / Chefdeville, M / Chen, C / Chen, S / Chernov, A / Chernyshenko, S / Chobanova, V / Cholak, S / Chrzaszcz, M / Chubykin, A / Chulikov, V / Ciambrone, P / Cicala, M F / Cid Vidal, X / Ciezarek, G / Cifra, P / Ciullo, G / Clarke, P E L / Clemencic, M / Cliff, H V / Closier, J / Cobbledick, J L / Coco, V / Coelho, J A B / Cogan, J / Cogneras, E / Cojocariu, L / Collins, P / Colombo, T / Congedo, L / Contu, A / Cooke, N / Corredoira, I / Corti, G / Couturier, B / Craik, D C / Cruz Torres, M / Currie, R / Da Silva, C L / Dadabaev, S / Dai, L / Dai, X / Dall'Occo, E / Dalseno, J / D'Ambrosio, C / Daniel, J / Danilina, A / d'Argent, P / Davies, J E / Davis, A / De Aguiar Francisco, O / de Boer, J / De Bruyn, K / De Capua, S / De Cian, M / De Freitas Carneiro Da Graca, U / De Lucia, E / De Miranda, J M / De Paula, L / De Serio, M / De Simone, D / De Simone, P / De Vellis, F / de Vries, J A / Dean, C T / Debernardis, F / Decamp, D / Dedu, V / Del Buono, L / Delaney, B / Dembinski, H-P / Denysenko, V / Deschamps, O / Dettori, F / Dey, B / Di Nezza, P / Diachkov, I / Didenko, S / Dieste Maronas, L / Ding, S / Dobishuk, V / Dolmatov, A / Dong, C / Donohoe, A M / Dordei, F / Dos Reis, A C / Douglas, L / Downes, A G / Duda, P / Dudek, M W / Dufour, L / Duk, V / Durante, P / Duras, M M / Durham, J M / Dutta, D / Dziurda, A / Dzyuba, A / Easo, S / Egede, U / Egorychev, V / Eirea Orro, C / Eisenhardt, S / Ejopu, E / Ek-In, S / Eklund, L / Elashri, M E / Ellbracht, J / Ely, S / Ene, A / Epple, E / Escher, S / Eschle, J / Esen, S / Evans, T / Fabiano, F / Falcao, L N / Fan, Y / Fang, B / Fantini, L / Faria, M / Farry, S / Fazzini, D / Felkowski, L F / Feo, M / Fernandez Gomez, M / Fernez, A D / Ferrari, F / Ferreira Lopes, L / Ferreira Rodrigues, F / Ferreres Sole, S / Ferrillo, M / Ferro-Luzzi, M / Filippov, S / Fini, R A / Fiorini, M / Firlej, M / Fischer, K M / Fitzgerald, D S / Fitzpatrick, C / Fiutowski, T / Fleuret, F / Fontana, M / Fontanelli, F / Forty, R / Foulds-Holt, D / Franco Lima, V / Franco Sevilla, M / Frank, M / Franzoso, E / Frau, G / Frei, C / Friday, D A / Frontini, L / Fu, J / Fuehring, Q / Fulghesu, T / Gabriel, E / Galati, G / Galati, M D / Gallas Torreira, A / Galli, D / Gambetta, S / Gandelman, M / Gandini, P / Gao, Y / Garau, M / Garcia Martin, L M / Garcia Moreno, P / García Pardiñas, J / Garcia Plana, B / Garcia Rosales, F A / Garrido, L / Gaspar, C / Geertsema, R E / Gerick, D / Gerken, L L / Gersabeck, E / Gersabeck, M / Gershon, T / Giambastiani, L / Gibson, V / Giemza, H K / Gilman, A L / Giovannetti, M / Gioventù, A / Gironella Gironell, P / Giugliano, C / Giza, M A / Gizdov, K / Gkougkousis, E L / Gligorov, V V / Göbel, C / Golobardes, E / Golubkov, D / Golutvin, A / Gomes, A / Gomez Fernandez, S / Goncalves Abrantes, F / Goncerz, M / Gong, G / Gorelov, I V / Gotti, C / Grabowski, J P / Grammatico, T / Granado Cardoso, L A / Graugés, E / Graverini, E / Graziani, G / Grecu, A T / Greeven, L M / Grieser, N A / Grillo, L / Gromov, S / Gruberg Cazon, B R / Gu, C / Guarise, M / Guittiere, M / Günther, P A / Gushchin, E / Guth, A / Guz, Y / Gys, T / Hadavizadeh, T / Hadjivasiliou, C / Haefeli, G / Haen, C / Haimberger, J / Haines, S C / Halewood-Leagas, T / Halvorsen, M M / Hamilton, P M / Hammerich, J / Han, Q / Han, X / Hansen, E B / Hansmann-Menzemer, S / Hao, L / Harnew, N / Harrison, T / Hasse, C / Hatch, M / He, J / Heijhoff, K / Hemmer, F H / Henderson, C / Henderson, R D L / Hennequin, A M / Hennessy, K / Henry, L / Herd, J / Heuel, J / Hicheur, A / Hill, D / Hilton, M / Hollitt, S E / Horswill, J / Hou, R / Hou, Y / Hu, J / Hu, W / Hu, X / Huang, W / Huang, X / Hulsbergen, W / Hunter, R J / Hushchyn, M / Hutchcroft, D / Ibis, P / Idzik, M / Ilin, D / Ilten, P / Inglessi, A / Iniukhin, A / Ishteev, A / Ivshin, K / Jacobsson, R / Jage, H / Jaimes Elles, S J / Jakobsen, S / Jans, E / Jashal, B K / Jawahery, A / Jevtic, V / Jiang, E / Jiang, X / Jiang, Y / John, M / Johnson, D / Jones, C R / Jones, T P / Jost, B / Jurik, N / Juszczak, I / Kandybei, S / Kang, Y / Karacson, M / Karpenkov, D / Karpov, M / Kautz, J W / Keizer, F / Keller, D M / Kenzie, M / Ketel, T / Khanji, B / Kharisova, A / Kholodenko, S / Khreich, G / Kirn, T / Kirsebom, V S / Kitouni, O / Klaver, S / Kleijne, N / Klimaszewski, K / Kmiec, M R / Koliiev, S / Kolk, L / Kondybayeva, A / Konoplyannikov, A / Kopciewicz, P / Kopecna, R / Koppenburg, P / Korolev, M / Kostiuk, I / Kot, O / Kotriakhova, S / Kozachuk, A / Kravchenko, P / Kravchuk, L / Krawczyk, R D / Kreps, M / Kretzschmar, S / Krokovny, P / Krupa, W / Krzemien, W / Kubat, J / Kubis, S / Kucewicz, W / Kucharczyk, M / Kudryavtsev, V / Kulikova, E K / Kupsc, A / Lacarrere, D / Lafferty, G / Lai, A / Lampis, A / Lancierini, D / Landesa Gomez, C / Lane, J J / Lane, R / Langenbruch, C / Langer, J / Lantwin, O / Latham, T / Lazzari, F / Lazzaroni, M / Le Gac, R / Lee, S H / Lefèvre, R / Leflat, A / Legotin, S / Lenisa, P / Leroy, O / Lesiak, T / Leverington, B / Li, A / Li, H / Li, K / Li, P / Li, P-R / Li, S / Li, T / Li, Y / Li, Z / Liang, X / Lin, C / Lin, T / Lindner, R / Lisovskyi, V / Litvinov, R / Liu, G / Liu, H / Liu, Q / Liu, S / Lobo Salvia, A / Loi, A / Lollini, R / Lomba Castro, J / Longstaff, I / Lopes, J H / Lopez Huertas, A / López Soliño, S / Lovell, G H / Lu, Y / Lucarelli, C / Lucchesi, D / Luchuk, S / Lucio Martinez, M / Lukashenko, V / Luo, Y / Lupato, A / Luppi, E / Lusiani, A / Lynch, K / Lyu, X-R / Ma, R / Maccolini, S / Machefert, F / Maciuc, F / Mackay, I / Macko, V / Madhan Mohan, L R / Maevskiy, A / Maisuzenko, D / Majewski, M W / Malczewski, J J / Malde, S / Malecki, B / Malinin, A / Maltsev, T / Manca, G / Mancinelli, G / Mancuso, C / Manera Escalero, R / Manuzzi, D / Manzari, C A / Marangotto, D / Marchand, J F / Marconi, U / Mariani, S / Marin Benito, C / Marks, J / Marshall, A M / Marshall, P J / Martelli, G / Martellotti, G / Martinazzoli, L / Martinelli, M / Martinez Santos, D / Martinez Vidal, F / Massafferri, A / Materok, M / Matev, R / Mathad, A / Matiunin, V / Matteuzzi, C / Mattioli, K R / Mauri, A / Maurice, E / Mauricio, J / Mazurek, M / McCann, M / Mcconnell, L / McGrath, T H / McHugh, N T / McNab, A / McNulty, R / Mead, J V / Meadows, B / Meier, G / Melnychuk, D / Meloni, S / Merk, M / Merli, A / Meyer Garcia, L / Miao, D / Mikhasenko, M / Milanes, D A / Millard, E / Milovanovic, M / Minard, M-N / Minotti, A / Miralles, T / Mitchell, S E / Mitreska, B / Mitzel, D S / Mödden, A / Mohammed, R A / Moise, R D / Mokhnenko, S / Mombächer, T / Monk, M / Monroy, I A / Monteil, S / Morello, G / Morello, M J / Morgenthaler, M P / Moron, J / Morris, A B / Morris, A G / Mountain, R / Mu, H / Muhammad, E / Muheim, F / Mulder, M / Müller, K / Murphy, C H / Murray, D / Murta, R / Muzzetto, P / Naik, P / Nakada, T / Nandakumar, R / Nanut, T / Nasteva, I / Needham, M / Neri, N / Neubert, S / Neufeld, N / Neustroev, P / Newcombe, R / Nicolini, J / Nicotra, D / Niel, E M / Nieswand, S / Nikitin, N / Nolte, N S / Normand, C / Novoa Fernandez, J / Nowak, G N / Nunez, C / Oblakowska-Mucha, A / Obraztsov, V / Oeser, T / Okamura, S / Oldeman, R / Oliva, F / Onderwater, C J G / O'Neil, R H / Otalora Goicochea, J M / Ovsiannikova, T / Owen, P / Oyanguren, A / Ozcelik, O / Padeken, K O / Pagare, B / Pais, P R / Pajero, T / Palano, A / Palutan, M / Pan, Y / Panshin, G / Paolucci, L / Papanestis, A / Pappagallo, M / Pappalardo, L L / Pappenheimer, C / Parker, W / Parkes, C / Passalacqua, B / Passaleva, G / Pastore, A / Patel, M / Patrignani, C / Pawley, C J / Pellegrino, A / Pepe Altarelli, M / Perazzini, S / Pereima, D / Pereiro Castro, A / Perret, P / Petridis, K / Petrolini, A / Petrov, A / Petrucci, S / Petruzzo, M / Pham, H / Philippov, A / Piandani, R / Pica, L / Piccini, M / Pietrzyk, B / Pietrzyk, G / Pili, M / Pinci, D / Pisani, F / Pizzichemi, M / Placinta, V / Plews, J / Plo Casasus, M / Polci, F / Poli Lener, M / Poluektov, A / Polukhina, N / Polyakov, I / Polycarpo, E / Ponce, S / Popov, D / Poslavskii, S / Prasanth, K / Promberger, L / Prouve, C / Pugatch, V / Puill, V / Punzi, G / Qi, H R / Qian, W / Qin, N / Qu, S / Quagliani, R / Raab, N V / Rachwal, B / Rademacker, J H / Rajagopalan, R / Rama, M / Ramos Pernas, M / Rangel, M S / Ratnikov, F / Raven, G / Rebollo De Miguel, M / Redi, F / Reich, J / Reiss, F / Remon Alepuz, C / Ren, Z / Resmi, P K / Ribatti, R / Ricci, A M / Ricciardi, S / Richardson, K / Richardson-Slipper, M / Rinnert, K / Robbe, P / Robertson, G / Rodrigues, A B / Rodrigues, E / Rodriguez Fernandez, E / Rodriguez Lopez, J A / Rodriguez Rodriguez, E / Rolf, D L / Rollings, A / Roloff, P / Romanovskiy, V / Romero Lamas, M / Romero Vidal, A / Roth, J D / Rotondo, M / Rudolph, M S / Ruf, T / Ruiz Fernandez, R A / Ruiz Vidal, J / Ryzhikov, A / Ryzka, J / Saborido Silva, J J / Sagidova, N / Sahoo, N / Saitta, B / Salomoni, M / Sanchez Gras, C / Sanderswood, I / Santacesaria, R / Santamarina Rios, C / Santimaria, M / Santovetti, E / Saranin, D / Sarpis, G / Sarpis, M / Sarti, A / Satriano, C / Satta, A / Saur, M / Savrina, D / Sazak, H / Scantlebury Smead, L G / Scarabotto, A / Schael, S / Scherl, S / Schiller, M / Schindler, H / Schmelling, M / Schmidt, B / Schmitt, S / Schneider, O / Schopper, A / Schubiger, M / Schulte, S / Schune, M H / Schwemmer, R / Sciascia, B / Sciuccati, A / Sellam, S / Semennikov, A / Senghi Soares, M / Sergi, A / Serra, N / Sestini, L / Seuthe, A / Shang, Y / Shangase, D M / Shapkin, M / Shchemerov, I / Shchutska, L / Shears, T / Shekhtman, L / Shen, Z / Sheng, S / Shevchenko, V / Shi, B / Shields, E B / Shimizu, Y / Shmanin, E / Shorkin, R / Shupperd, J D / Siddi, B G / Silva Coutinho, R / Simi, G / Simone, S / Singla, M / Skidmore, N / Skuza, R / Skwarnicki, T / Slater, M W / Smallwood, J C / Smeaton, J G / Smith, E / Smith, K / Smith, M / Snoch, A / Soares Lavra, L / Sokoloff, M D / Soler, F J P / Solomin, A / Solovev, A / Solovyev, I / Song, R / Souza De Almeida, F L / Souza De Paula, B / Spaan, B / Spadaro Norella, E / Spedicato, E / Spiridenkov, E / Spradlin, P / Sriskaran, V / Stagni, F / Stahl, M / Stahl, S / Stanislaus, S / Stein, E N / Steinkamp, O / Stenyakin, O / Stevens, H / Stone, S / Strekalina, D / Su, Y S / Suljik, F / Sun, J / Sun, L / Sun, Y / Svihra, P / Swallow, P N / Swientek, K / Szabelski, A / Szumlak, T / Szymanski, M / Tan, Y / Taneja, S / Tat, M D / Terentev, A / Teubert, F / Thomas, E / Thompson, D J D / Thomson, K A / Tilquin, H / Tisserand, V / T'Jampens, S / Tobin, M / Tomassetti, L / Tonani, G / Tong, X / Torres Machado, D / Tou, D Y / Trilov, S M / Trippl, C / Tuci, G / Tuning, N / Ukleja, A / Unverzagt, D J / Usachov, A / Ustyuzhanin, A / Uwer, U / Vagner, A / Vagnoni, V / Valassi, A / Valenti, G / Valls Canudas, N / Van Dijk, M / Van Hecke, H / van Herwijnen, E / Van Hulse, C B / van Veghel, M / Vazquez Gomez, R / Vazquez Regueiro, P / Vázquez Sierra, C / Vecchi, S / Velthuis, J J / Veltri, M / Venkateswaran, A / Veronesi, M / Vesterinen, M / Vieira, D / Vieites Diaz, M / Vilasis-Cardona, X / Vilella Figueras, E / Villa, A / Vincent, P / Volle, F C / Vom Bruch, D / Vorobyev, A / Vorobyev, V / Voropaev, N / Vos, K / Vrahas, C / Walsh, J / Walton, E J / Wan, G / Wang, C / Wang, G / Wang, J / Wang, M / Wang, R / Wang, X / Wang, Y / Wang, Z / Ward, J A / Watson, N K / Websdale, D / Wei, Y / Westhenry, B D C / White, D J / Whitehead, M / Wiederhold, A R / Wiedner, D / Wilkinson, G / Wilkinson, M K / Williams, I / Williams, M / Williams, M R J / Williams, R / Wilson, F F / Wislicki, W / Witek, M / Witola, L / Wong, C P / Wormser, G / Wotton, S A / Wu, H / Wu, J / Wyllie, K / Xiang, Z / Xie, Y / Xu, A / Xu, J / Xu, L / Xu, M / Xu, Q / Xu, Z / Yang, D / Yang, S / Yang, X / Yang, Y / Yang, Z / Yeomans, L E / Yeroshenko, V / Yeung, H / Yin, H / Yu, J / Yuan, X / Zaffaroni, E / Zavertyaev, M / Zdybal, M / Zeng, M / Zhang, C / Zhang, D / Zhang, L / Zhang, S / Zhang, Y / Zhao, Y / Zharkova, A / Zhelezov, A / Zheng, Y / Zhou, T / Zhou, X / Zhou, Y / Zhovkovska, V / Zhu, X / Zhu, Z / Zhukov, V / Zou, Q / Zucchelli, S / Zuliani, D / Zunica, G

    Physical review letters

    2023  Volume 131, Issue 11, Page(s) 111802

    Abstract: The ratios of branching fractions R(D^{*})≡B(B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]→D^{*}μ^ ... ν[over ¯]_{μ}) and R(D^{0})≡B(B^{-}→D^{0}τ^{-}ν[over ¯]_{τ})/B(B^{-}→D^{0}μ^{-}ν[over ¯]_{μ}) are ... is identified in the decay mode τ^{-}→μ^{-}ν_{τ}ν[over ¯]_{μ}. The measured values are R(D^{*})=0 ...

    Abstract The ratios of branching fractions R(D^{*})≡B(B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]→D^{*}μ^{-}ν[over ¯]_{μ}) and R(D^{0})≡B(B^{-}→D^{0}τ^{-}ν[over ¯]_{τ})/B(B^{-}→D^{0}μ^{-}ν[over ¯]_{μ}) are measured, assuming isospin symmetry, using a sample of proton-proton collision data corresponding to 3.0  fb^{-1} of integrated luminosity recorded by the LHCb experiment during 2011 and 2012. The tau lepton is identified in the decay mode τ^{-}→μ^{-}ν_{τ}ν[over ¯]_{μ}. The measured values are R(D^{*})=0.281±0.018±0.024 and R(D^{0})=0.441±0.060±0.066, where the first uncertainty is statistical and the second is systematic. The correlation between these measurements is ρ=-0.43. The results are consistent with the current average of these quantities and are at a combined 1.9 standard deviations from the predictions based on lepton flavor universality in the standard model.
    Language English
    Publishing date 2023-09-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208853-8
    ISSN 1079-7114 ; 0031-9007
    ISSN (online) 1079-7114
    ISSN 0031-9007
    DOI 10.1103/PhysRevLett.131.111802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.

    Della Vecchia, Alessandra / De Luca, Ciro / Becattini, Lucrezia / Curto, Letizia / Ferrari, Elena / Siciliano, Gabriele / Gori, Sara / Baldacci, Filippo

    Biomedicines

    2024  Volume 12, Issue 3

    Abstract: ... on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on migraine comorbidities of depression, anxiety, and ... with anti-CGRP/R mAbs for 3 months. Seventy-seven patients were enrolled with either HFEM (21%) or CM (79 ... ameliorated only in responders. We found that anti-CGRP/R antibodies improved pain together with affection ...

    Abstract The study aimed to evaluate the effects of monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on migraine comorbidities of depression, anxiety, and fatigue in patients resistant to traditional therapies. The issue addressed in this study is pivotal to unveiling the role of this neurotransmitter beyond pain processing. We conducted an open-label prospective study assessing comorbidities in patients with high frequency (HFEM) and chronic migraine (CM), medication overuse headache (MOH), and resistance to traditional prophylaxis. All patients were treated with anti-CGRP/R mAbs for 3 months. Seventy-seven patients were enrolled with either HFEM (21%) or CM (79%) with or without MOH (56% and 44%, respectively). We identified 21 non-responders (27%) and 56 responders (73%), defined on the reduction ≥50% of headache frequency. The two groups were highly homogeneous for the investigated comorbidities. Disease severity in terms of headache frequency, migraine-related disability, and affective comorbid symptoms was reduced in both groups with different thresholds; allodynia and fatigue were ameliorated only in responders. We found that anti-CGRP/R antibodies improved pain together with affection, fatigue, and sensory sensitization in a cohort of migraine patients resistant to traditional prophylaxis. Our results offer novel perspectives on the early efficacy of anti-CGRP/R mAbs in difficult-to-treat patients focusing on clinical features other than pain relief.
    Language English
    Publishing date 2024-03-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines12030677
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Recommendations on diagnosis and antimicrobial treatment of infections after anterior cruciate ligament reconstruction (ACL-R) endorsed by ESSKA and EBJIS.

    Renz, Nora / Madjarevic, Tomislav / Ferrari, Matteo / Becker, Roland / Ravn, Christen / Vogely, Charles / Pérez-Prieto, Daniel

    The Journal of infection

    2023  Volume 86, Issue 6, Page(s) 543–551

    Abstract: Infection after anterior cruciate ligament reconstruction (ACL-R) is a rare but devastating ... orthopedic surgeons and other healthcare professionals who care for patients with infections after ACL-R ... in the field, and cover the management of infections after ACL-R with a special focus on etiology, diagnosis ...

    Abstract Infection after anterior cruciate ligament reconstruction (ACL-R) is a rare but devastating complication affecting predominantly young and sportive individuals. A timely and correct diagnosis as well as optimized management is paramount to circumvent serious sequelae and compromise in life quality. These recommendations are primarily intended for use by infectious disease specialists and microbiologists, but also orthopedic surgeons and other healthcare professionals who care for patients with infections after ACL-R. They are based on evidence mainly originating from observational studies and opinions of experts in the field, and cover the management of infections after ACL-R with a special focus on etiology, diagnosis, antimicrobial treatment and prevention. Comprehensive recommendations on surgical treatment and rehabilitation are presented separately in a document primarily addressing orthopedic professionals.
    MeSH term(s) Humans ; Anterior Cruciate Ligament Injuries/surgery ; Anterior Cruciate Ligament Injuries/diagnosis ; Anterior Cruciate Ligament Reconstruction/adverse effects ; Anti-Infective Agents/therapeutic use ; Debridement
    Chemical Substances Anti-Infective Agents
    Language English
    Publishing date 2023-04-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2023.03.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Erratum: Benelli, R., et al. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer.

    Benelli, Roberto / Costa, Delfina / Mastracci, Luca / Grillo, Federica / Olsen, Mark Jon / Barboro, Paola / Poggi, Alessandro / Ferrari, Nicoletta

    Cancers

    2020  Volume 12, Issue 5

    Abstract: The authors wish to make the following corrections to this paper [ ... ]. ...

    Abstract The authors wish to make the following corrections to this paper [...].
    Language English
    Publishing date 2020-05-13
    Publishing country Switzerland
    Document type Journal Article ; Published Erratum
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12051226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.

    Rigacci, Luigi / Annibali, Ombretta / Kovalchuk, Sofya / Bonifacio, Elisabetta / Pregnolato, Francesca / Angrilli, Francesco / Vitolo, Umberto / Pozzi, Samantha / Broggi, Serena / Luminari, Stefano / Merli, Francesco / Spina, Michele / Bolis, Silvia / Margiotta-Casaluci, Gloria / Scalzulli, Rosario / Cox, Christina / Mamusa, Angela Maria / Santoro, Armando / Zinzani, Pier Luigi /
    Ferrari, Samantha / Gini, Guido / Vigliotti, Maria Luigia / Mulè, Antonino / Flenghi, Leonardo

    Hematological oncology

    2020  Volume 38, Issue 4, Page(s) 478–486

    Abstract: ... in using NPLD. Nine hundred and forty-six consecutive pts treated with R-COMP (doxorubicin was substituted ... Our findings strongly support that including R-COMP is effective and safe when the population is at high risk ...

    Abstract Doxorubicin is the most effective single agent in the treatment of non-Hodgkin's lymphoma (NHL). Its use is limited because of the cardiac toxicity primarily in elderly patients (pts) and in pts with history of cardiac disease. Liposomal doxorubicin has been proven to reduce cardiotoxicity. The aim of this retrospective study was the use of nonpeghylated liposomal doxorubicin (NPLD) in term of efficacy, response rate and incidence of cardiac events. We retrospectively collected the experience of 33 Hematological Italian Centers in using NPLD. Nine hundred and forty-six consecutive pts treated with R-COMP (doxorubicin was substituted with NPLD, Myocet) were collected. Median age was 74 years, the reasons for use of NPLD were: age (466 pts), cardiac disease (298 pts), uncontrolled hypertension (126 pts), other reasons (56 pts). According to clinicians' evaluation, 49.9% of pts would not have used standard doxorubicin for different situations (age, cardiomyopathy, previous use of doxorubicin, and uncontrolled hypertension). Overall 687 pts (72.6%) obtained a complete remission (CR). About 5% (n = 51) of subjects developed major cardiotoxic events including heart failure (N = 31), ischemic heart disease (N = 16), acute heart attack (N = 3), and acute pulmonary oedema (N = 1). After a median follow-up of 32 months, 651 pts were alive and the overall survival (OS) was 72%. After a median observation period of 23 months disease free survival (DFS) was 58%. Either in univariate or in multivariate analysis OS and DFS were not significantly affected by age or cardiac disease. Our findings strongly support that including R-COMP is effective and safe when the population is at high risk of cardiac events and negatively selected. Moreover, the use of this NPLD permitted that about half of our population had the opportunity to receive the best available treatment.
    MeSH term(s) Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Comorbidity ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Female ; Follow-Up Studies ; Heart Diseases/physiopathology ; Humans ; Italy/epidemiology ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/epidemiology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Polyethylene Glycols/administration & dosage ; Prognosis ; Retrospective Studies ; Rituximab/administration & dosage ; Survival Rate ; Vincristine/administration & dosage
    Chemical Substances liposomal doxorubicin ; Polyethylene Glycols (3WJQ0SDW1A) ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2020-07-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2764
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Translation of the UK-Birth-Satisfaction-Scale-Revised (BSS-R) into Brazilian (Portuguese) and description of initial measurement properties.

    Ferrari, Renata Bullio / Martin, Colin / Hollins Martin, Caroline / de Souza, Felipe Granado / Clini, Julia Vale / Onofre, Laiane Barros Oliveira / Diniz Zanetti, Miriam Raquel

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

    2021  Volume 35, Issue 25, Page(s) 6373–6379

    Abstract: ... quality of relationships with her partner and family. The UK-Birth-Satisfaction-Scale-Revised (UK-BSS-R ... adapt the UK-BSS-R into Brazilian (Portuguese) and validate its key measurement properties.: Methods ... validity and reliability of the Brazilian (Portuguese)-BSS-R.: Participants: Data was gathered from (: Results ...

    Abstract Rationale: The concept of birth satisfaction embraces many factors, which include for example perceived quality of care provision, stress experienced, and personal coping strategies. A woman's birth experience has the power to affect her mental health, decisions surrounding future birth planning, and quality of relationships with her partner and family. The UK-Birth-Satisfaction-Scale-Revised (UK-BSS-R) is currently recommended as the tool of choice by the International Consortium for Health Outcome Measures (ICHOM) for measuring women's experiences of childbirth. It was therefore considered important to translate and validate this scale for use in a Brazilian context.
    Objective: To translate and culturally adapt the UK-BSS-R into Brazilian (Portuguese) and validate its key measurement properties.
    Methods: A repeated-measures survey was conducted for the purpose of examining factor structure, validity and reliability of the Brazilian (Portuguese)-BSS-R.
    Participants: Data was gathered from (
    Results: The initial measurement characteristics of the Brazilian (Portuguese)-BSS-R in terms of Intraclass Correlational Coefficient, Standard Error of Measurement and minimal detectable change were found to be excellent.
    Conclusion: The Brazilian (Portuguese)-BSS-R is now considered to be a valid and reliable multidimensional psychometric instrument for measuring birth satisfaction in a Brazilian Portuguese population of postnatal women. This translation was found to be conceptually consistent with the original English-language version (UK-BSS-R) and to have an excellent initial measurement characteristics profile. The direction of future research is indicated, specifically to undertake a thorough psychometric evaluation of the Brazilian (Portuguese)-BSS-R in a larger sample.
    MeSH term(s) Humans ; Pregnancy ; Female ; Brazil ; Reproducibility of Results ; Personal Satisfaction ; Language ; Portugal ; Psychometrics/methods ; Surveys and Questionnaires ; United Kingdom
    Language English
    Publishing date 2021-05-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2077261-0
    ISSN 1476-4954 ; 1057-0802 ; 1476-7058
    ISSN (online) 1476-4954
    ISSN 1057-0802 ; 1476-7058
    DOI 10.1080/14767058.2021.1913579
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.

    Ferrari, Myriam / Pengo, Vittorio / Barolo, Massimiliano / Bezzo, Fabrizio / Padrini, Roberto

    European journal of clinical pharmacology

    2017  Volume 73, Issue 6, Page(s) 699–707

    Abstract: ... model to characterise the contribution of (S)- and (R)-warfarin to the anticoagulant effect on patients ... from the first dose and during chronic treatment at INR stabilization. Plasma concentrations of (S)- and (R)-W ... potency of (R)-W. Two parallel compartment chains with different transit times (MTT: Results: The model ...

    Abstract Purpose: The purpose of this study is to develop a new pharmacokinetic-pharmacodynamic (PK-PD) model to characterise the contribution of (S)- and (R)-warfarin to the anticoagulant effect on patients in treatment with rac-warfarin.
    Methods: Fifty-seven patients starting warfarin (W) therapy were studied, from the first dose and during chronic treatment at INR stabilization. Plasma concentrations of (S)- and (R)-W and INRs were measured 12, 36 and 60 h after the first dose and at steady state 12-14 h after dosing. Patients were also genotyped for the G>A VKORC1 polymorphism. The PK-PD model assumed a linear relationship between W enantiomer concentration and INR and included a scaling factor k to account for a different potency of (R)-W. Two parallel compartment chains with different transit times (MTT
    Results: The model satisfactorily described the mean time-course of INR, both after the initial dose and during long-term treatment. (R)-W contributed to the rac-W anticoagulant effect with a potency of about 27% that of (S)-W. This effect was independent of VKORC1 genotype. As expected, the slope of the PK/PD linear correlation increased stepwise from GG to GA and from GA to AA VKORC1 genotype (0.71, 0.90 and 1.49, respectively).
    Conclusions: Our PK-PD linear model can quantify the partial pharmacodynamic activity of (R)-W in patients contemporaneously exposed to therapeutic (S)-W plasma levels. This concept may be useful in improving the performance of future algorithms aiming at identifying the most appropriate W maintenance dose.
    Language English
    Publishing date 2017-06
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-017-2248-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.

    Marko, Martha / Posekany, Alexandra / Szabo, Simon / Scharer, Sebastian / Kiechl, Stefan / Knoflach, Michael / Serles, Wolfgang / Ferrari, Julia / Lang, Wilfried / Sommer, Peter / Greisenegger, Stefan

    Stroke

    2020  Volume 51, Issue 4, Page(s) 1240–1247

    Abstract: Background and Purpose- Frequencies of treatment with r-tPA (recombinant ... demographic and clinical factors on r-tPA treatment as well as estimates of future trajectories are limited ... We evaluated time trends and future trajectories of r-tPA treatment in patients with acute stroke and ...

    Abstract Background and Purpose- Frequencies of treatment with r-tPA (recombinant tissue-type plasminogen activator) are increasing over the past 15 years. However, published data on the influence of various demographic and clinical factors on r-tPA treatment as well as estimates of future trajectories are limited. We evaluated time trends and future trajectories of r-tPA treatment in patients with acute stroke and the influence of various factors on r-tPA treatment by analyzing data of 103 970 patients enrolled in the Austrian Stroke Unit Registry from 2006 to 2018, of which 18 953 were treated with r-tPA. Methods- Time trends of r-tPA-treatment were investigated in predefined subgroups (minor/major stroke, age, anterior/posterior circulation stroke); limited exponential time series models were calculated to estimate future trends of r-tPA-treatment. Logistic regression models were calculated to estimate the influence of clinical variables on r-tPA-treatment. Results- Overall, r-tPA treatment frequencies increased from 9.9% in 2006 to 21.8% in 2018. We observed a particular increase in patients >80 years, patients presenting with a National Institutes of Health Stroke Scale Score of 2 to 3, patients with posterior circulation stroke, patients with wake-up stroke, and patients without atrial fibrillation. Forecast of overall r-tPA frequencies predicted a further but flattened increase up to 24% by 2025. Logistic regression of time-dependent associations of clinical variables with r-tPA-treatment revealed increasing odds of r-tPA-treatment in patients with a posterior circulation stroke and decreasing odds of r-tPA-treatment in patients with atrial fibrillation. Conclusions- We observed a positive development of r-tPA-treatment frequencies mirroring increasing confidence with intravenous thrombolysis in clinical practice; however, decreasing odds of r-tPA-treatment over time in patients with atrial fibrillation deserve particular attention.
    MeSH term(s) Aged ; Aged, 80 and over ; Austria/epidemiology ; Brain Ischemia/diagnosis ; Brain Ischemia/drug therapy ; Brain Ischemia/epidemiology ; Female ; Fibrinolytic Agents/administration & dosage ; Humans ; Male ; Middle Aged ; Recombinant Proteins/administration & dosage ; Registries ; Stroke/diagnosis ; Stroke/drug therapy ; Stroke/epidemiology ; Tissue Plasminogen Activator/administration & dosage ; Treatment Outcome
    Chemical Substances Fibrinolytic Agents ; Recombinant Proteins ; Tissue Plasminogen Activator (EC 3.4.21.68)
    Language English
    Publishing date 2020-03-02
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 80381-9
    ISSN 1524-4628 ; 0039-2499 ; 0749-7954
    ISSN (online) 1524-4628
    ISSN 0039-2499 ; 0749-7954
    DOI 10.1161/STROKEAHA.119.027921
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis.

    Noble, Stephane / Stortecky, Stefan / Heg, Dik / Tueller, David / Jeger, Raban / Toggweiler, Stefan / Ferrari, Enrico / Nietlispach, Fabian / Taramasso, Maurizio / Maisano, Francesco / Grünenfelder, Jürg / Jüni, Peter / Huber, Christoph / Carrel, Thierry / Windecker, Stephan / Wenaweser, Peter / Roffi, Marco

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

    2017  Volume 12, Issue 18, Page(s) e2170–e2176

    Abstract: ... with the new-generation self-expanding Medtronic Evolut R prosthesis in comparison with its predecessor ... the Medtronic CoreValve, are scarce. The aim of this study was to assess the safety and efficacy of the Evolut R ... generation Medtronic Evolut R (September 2014 - February 2016) and the Medtronic CoreValve (February 2011 ...

    Abstract Aims: Data on procedural and clinical outcomes after transcatheter aortic valve implantation (TAVI) with the new-generation self-expanding Medtronic Evolut R prosthesis in comparison with its predecessor, the Medtronic CoreValve, are scarce. The aim of this study was to assess the safety and efficacy of the Evolut R device compared with the former-generation CoreValve.
    Methods and results: In a nationwide, prospective, multicentre cohort study, outcomes of consecutive transfemoral TAVI patients treated with the new-generation Medtronic Evolut R (September 2014 - February 2016) and the Medtronic CoreValve (February 2011 - February 2016) were investigated. Events were reported according to VARC-2 and adjudicated by a clinical events committee. During the study period, 317 and 678 consecutive patients underwent TAVI with the Evolut R and the CoreValve bioprosthesis, respectively. Baseline clinical characteristics between the groups were comparable, although Evolut R patients were lower risk according to the STS score (4.8±3.4% vs. 6.9±5.0%, p<0.001) and logistic EuroSCORE (17.3±13% vs. 20.1±13%, p=0.009). Implantation of the Evolut R was associated with a lower use of predilatation (48.1% vs. 72.4%, p<0.001), a shorter procedure time (67.9±36 min vs. 76.7±42 min, p=0.002), and less contrast dye use during the procedure (155.2±98 ml vs. 208.0±117 ml, p<0.001). Post-procedural mean gradient was comparable (7.4±4.7 mmHg vs. 7.5±5.0 mmHg), as were the 30-day rates of moderate to severe aortic regurgitation (8.5% vs. 10.5%), major vascular (9.8% vs. 10.3%) and life-threatening bleeding complications (5.4% vs. 5.3%), disabling stroke (1.9% vs. 1.6%), all-cause mortality (3.2% vs. 3.4%) as well as permanent pacemaker implantation (22.1% vs. 23.4%).
    Conclusions: Thirty-day clinical outcomes were favourable and comparable between the Evolut R and the CoreValve bioprosthesis.
    MeSH term(s) Aged ; Aged, 80 and over ; Bioprosthesis ; Female ; Humans ; Male ; Prospective Studies ; Registries ; Transcatheter Aortic Valve Replacement/instrumentation ; Transcatheter Aortic Valve Replacement/methods ; Transcatheter Aortic Valve Replacement/mortality ; Treatment Outcome
    Language English
    Publishing date 2017-04-07
    Publishing country France
    Document type Comparative Study ; Journal Article ; Multicenter Study
    ZDB-ID 2457174-X
    ISSN 1969-6213 ; 1774-024X
    ISSN (online) 1969-6213
    ISSN 1774-024X
    DOI 10.4244/EIJ-D-16-00677
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Psychosocial Cardiological Schedule-Revised (PCS-R) in a Cardiac Rehabilitation Unit

    Nicolò Granata / Ekaterina Nissanova / Valeria Torlaschi / Marina Ferrari / Martina Vigorè / Marinella Sommaruga / Elisabetta Angelino / Claudia Rizza / Alessandra Caprino / Antonia Pierobon

    Frontiers in Psychology, Vol

    Reflections Upon Data Collection (2010–2017) and New Challenges

    2020  Volume 11

    Abstract: ... version of the schedule was provided [PCS-Revised (PCS-R)].Results28 patients (aged 53.5 + 12.6 years, M ... the clinical experience, and the recent evidences from literature led to the PCS-R, incorporating ... requires neuropsychological assessment. The PCS-R could be considered in clinical practice as a useful ...

    Abstract IntroductionThe Psychosocial Cardiological Schedule (PCS) was developed as a screening tool for patients undergoing cardiac rehabilitation (CR) to detect clinically relevant psychosocial/cognitive problems requiring psychological assessment/intervention. Filled out by a trained nurse, it classifies patients according to their need or not for a psychological interview and intervention provided by the psychologist (PCS-Yes vs. PCS-No).AimsThe main aim was to compare PCS data collected, respectively, in 2010 and 2017, regarding patients’ socio-demographic characteristics, clinical variables, and the inclusion criteria for psychological counseling. Subsequently, the original Italian PCS was revised and an English version of the schedule was provided [PCS-Revised (PCS-R)].Results28 patients (aged 53.5 + 12.6 years, M = 20) of the 87 recruited in 2010 vs. 35 (aged 64.9 + 12.7 years, M = 28) of the 83 recruited in 2017 met the criteria for PCS-Yes: age < 55 years, social problems (living alone, no social support), manifest psychological/behavioral problems, suspected neuropsychological disorders, low prescription adherence, inadequate disease awareness. Comparing the two samples (2010 vs. 2017), clinical variables were similar, and the need for a psychological interview did not differ substantially (32.2 vs. 42.2%), but age increased significantly (PCS-Yes: 53.5 ± 12.6 vs. 64.9 ± 12.7 years, p = 0.001; PCS-No: 68.3 ± 8.0 vs. 75.0 ± 7.7 years, p = 0.0001). A significant increase was observed in the recommendation for neuropsychological assessment (3.6 vs. 25.7%, p = 0.02) to confirm eventual cognitive deficits. These results, the clinical experience, and the recent evidences from literature led to the PCS-R, incorporating a psychosocial screening, a psychological/neuropsychological deeper assessment, and a recommendation for a specific intervention to be carried out either during rehabilitation or in outpatient services.ConclusionThe data comparison highlight changes in the cardiac population, which is aging and more frequently requires neuropsychological assessment. The PCS-R could be considered in clinical practice as a useful screening tool to implement a timely coordinated interdisciplinary intervention, comprehensive of specific and tailored psychotherapeutic techniques.
    Keywords psychosocial screening ; psychological interview ; cardiac rehabilitation ; nursing ; interdisciplinary intervention ; rehabilitation medicine ; Psychology ; BF1-990
    Subject code 150
    Language English
    Publishing date 2020-07-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top